Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results

被引：0

作者：

Armstrong, April W. ^{[1
]}

Lebwohl, Mark ^{[2
]}

Warren, Richard B. ^{[3
,4
]}

Sofen, Howard ^{[5
]}

Imafuku, Shinichi ^{[6
]}

Ohtsuki, Mamitaro ^{[7
]}

Spelman, Lynda ^{[8
]}

Passeron, Thierry ^{[9
]}

Papp, Kim A. ^{[10
,11
]}

Kisa, Renata M. ^{[12
]}

Berger, Victoria ^{[12
,13
]}

Vritzali, Eleni

Hoyt, Kim ^{[12
]}

Colombo, Matthew J. ^{[12
]}

Banerjee, Subhashis ^{[12
]}

Strober, Bruce ^{[14
]}

Thaci, Diamant ^{[15
]}

Blauvelt, Andrew ^{[16
]}

机构：

[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA

[2] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

[3] Northern Care Alliance NHS Fdn Trust, Dermatol Ctr, Manchester, England

[4] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England

[5] Univ Calif Los Angeles, Sch Med & Dermatol Res Associates, Los Angeles, CA USA

[6] Fukuoka Univ, Fac Med, Fukuoka, Japan

[7] Jichi Med Univ, Tochigi, Japan

[8] Verac Clin Res, Brisbane, Qld, Australia

[9] Univ Cote Azur, Univ Hosp Nice, Nice, France

[10] Alliance Clin Res & Prob Med Res, Waterloo, ON, Canada

[11] Univ Toronto, Toronto, ON, Canada

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Bristol Myers Squibb, Sissach, Switzerland

[14] Yale Univ, New Haven, CT USA

[15] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[16] Oregon Med Res Ctr, Portland, OR USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0261

引用

页码：509 / 511

页数：3

共 50 条

[21] Plaque Psoriasis: Deucravacitinib versus Placebo or Apremilast
Lorenz, Judith
AKTUELLE DERMATOLOGIE, 2023, 49 (07) : 290 - 290
[22] Deucravacitinib in plaque psoriasis: a profile of its use
Arnold Lee
Drugs & Therapy Perspectives, 2023, 39 : 357 - 364
[23] Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials
Armstrong, April W.
Kircik, Leon
Stein Gold, Linda
Strober, Bruce
De Oliveira, Claudia H. M. C.
Vaile, John
Jou, Ying-Ming
Daamen, Carolin
Scharnitz, Thomas
Lebwohl, Mark
DERMATOLOGY AND THERAPY, 2025, 15 (04) : 1025 - 1035
[24] Topical medications for chronic plaque psoriasis: A 3-year longitudinal study in France
Mahe, Emmanuel
Moumane, Sarah-Hind
Foist, Murielle
DERMATOLOGIC THERAPY, 2021, 34 (02)
[25] A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice
Burlando, Martina
Salvi, Ilaria
Parodi, Aurora
Cozzani, Emanuele
DERMATOLOGY AND THERAPY, 2024, 14 (09) : 2645 - 2652
[26] Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial
Warren, R. B.
Lebwohl, M.
Sofen, H.
Piguet, V.
Augustin, M.
Brock, F.
Arendt, C.
Fierens, F.
Blauvelt, A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (12) : 2398 - 2408
[27] Safety and efficacy of ustekinumab in adolescent patients with moderate to severe plaque psoriasis: Results through 1 year of the phase 3 CADMUS trial
Landells, Ian
Marano, Collen
Hsu, Ming-Chun
Li, Shu
Eichenfield, Lawrence
Hoeger, Peter
Menter, Alan
Paller, Amy
Taieb, Alain
Randazzo, Bruce
Szapary, Philippe
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB202 - AB202
[28] Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
Merola, Joseph F.
Ferris, Laura K.
Sobell, Jeffrey M.
Sofen, Howard
Osborne, John
Vaile, John
Jou, Ying-Ming
Daamen, Carolin
Scotto, Julie
Scharnitz, Thomas
Lebwohl, Mark
DERMATOLOGY AND THERAPY, 2025, 15 (02) : 453 - 462
[29] Tazarotene gel: Efficacy and safety in plaque psoriasis
Weinstein, GD
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (02) : S33 - S38
[30] Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1
Crowley, Jeffrey
Korman, Neil J.
Spelman, Lynda
Igarashi, Atsuyuki
Gupta, Aditya K.
Mendelsohn, Alan M.
Rozzo, Stephen J.
Eads, Kimberly M.
Guenthner, Scott T.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB162 - AB162

← 1 2 3 4 5 →